Alzheimer's drug lecanemab slows cognitive decline but concerns linger

The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits